NUREXONE BIOLOGIC INC. (J90) - Total Liabilities

Latest as of December 2025: €1.32 Million EUR ≈ $1.55 Million USD

Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) has total liabilities worth €1.32 Million EUR (≈ $1.55 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore J90 net assets growth trend to track the company's year-over-year net asset growth rate.

NUREXONE BIOLOGIC INC. - Total Liabilities Trend (2021–2025)

This chart illustrates how NUREXONE BIOLOGIC INC.'s total liabilities have evolved over time, based on quarterly financial data.

NUREXONE BIOLOGIC INC. Competitors by Total Liabilities

The table below lists competitors of NUREXONE BIOLOGIC INC. ranked by their total liabilities.

Company	Country	Total Liabilities
Live Ventures Inc NASDAQ:LIVE	USA	$293.93 Million
CItech Co Ltd KO:004920	Korea	₩30.28 Billion
Drax Group PLC LSE:DRX	UK	GBX3.27 Billion
Atlantaa Limited NSE:ATLANTAA	India	Rs3.52 Billion
INFAC Corporation KO:023810	Korea	₩528.96 Billion
Elektrocieplownia Bedzin WAR:BDZ	Poland	zł9.97 Million
Eurotel SA WAR:ETL	Poland	zł96.72 Million
Deliveroo Holdings PLC LSE:ROO	UK	GBX580.90 Million

Liability Composition Analysis (2021–2025)

This chart breaks down NUREXONE BIOLOGIC INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of NUREXONE BIOLOGIC INC..

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.63	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NUREXONE BIOLOGIC INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NUREXONE BIOLOGIC INC. (2021–2025)

The table below shows the annual total liabilities of NUREXONE BIOLOGIC INC. from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.32 Million ≈ $1.55 Million	+94.85%
2024-12-31	€680.00K ≈ $794.99K	-65.67%
2023-12-31	€1.98 Million ≈ $2.32 Million	+183.81%
2022-12-31	€698.00K ≈ $816.04K	-57.93%
2021-12-31	€1.66 Million ≈ $1.94 Million	--

About NUREXONE BIOLOGIC INC.

F:J90 Germany Biotechnology

Market Cap

$32.39 Million

€27.71 Million EUR

Market Cap Rank

#23489 Global

#2051 in Germany

Share Price

€0.30

Change (1 day)

+2.38%

52-Week Range

€0.29 - €0.70

All Time High

€0.88